The United States Food and Drug Administration (USFDA) has concluded the inspection at Aurobindo Pharma’s wholly owned subsidiary-- Eugia Pharma Specialities’ Unit-II, a Formulation manufacturing facility, situated at Bhiwadi, Alwar, Rajasthan. USFDA had conducted an inspection from April 25, 2024 to May 3, 2024. The inspection closed with 7 observations. The observations are procedural in nature and will be responded to within the stipulated time.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.85 |
Dr. Reddys Lab | 5812.50 |
Cipla | 1403.90 |
Zydus Lifesciences | 1104.45 |
Lupin | 1661.90 |
View more.. |